Tahir Turk | Health Professions | Innovative Research Award

Published on by Invention Awards

Innovative Research Award

Tahir Turk
Dow University of Health Sciences, Australia

Tahir Turk
Affiliation Dow University of Health Sciences
Country Australia
Scopus ID 37091848000
Documents 20
Citations 278
h-index 9
Subject Area Health Professions
Event International Invention Awards
ORCID 0000-0002-8119-4171

Tahir Turk is a researcher associated with Dow University of Health Sciences whose scholarly activities focus on public health, health promotion, nutrition-sensitive social protection, social and behaviour change communication (SBCC), and water, sanitation and hygiene initiatives. His publication record demonstrates engagement with evidence-based interventions designed to improve health outcomes in diverse communities and low- and middle-income country settings. Through interdisciplinary collaborations, his work contributes to the understanding of behavioural determinants of health and the development of context-specific communication strategies.[1]

Abstract

This article reviews the academic profile of Tahir Turk and highlights contributions to public health research, nutrition-sensitive interventions, behavioural communication strategies, and WASH-related initiatives. His publications demonstrate a commitment to co-design methodologies, systematic evidence synthesis, and community-centered health promotion. The body of work reflects practical applications of behavioural science within public health programs and supports the advancement of effective communication frameworks for improving population health outcomes.[2]

Keywords

Public Health, Health Promotion, Social and Behaviour Change Communication, Nutrition, WASH, Community Engagement, Co-design Research, Systematic Review.

Introduction

Modern public health challenges increasingly require integrated approaches that combine behavioural science, community participation, and evidence-informed interventions. Tahir Turk’s research addresses these priorities through studies examining nutrition-sensitive social protection programs, obesity prevention strategies, and sanitation-related behavioural change initiatives. His work contributes to contemporary discussions regarding the implementation and evaluation of public health communication programs.[3]

Research Profile

According to available scholarly metrics, Tahir Turk has authored twenty indexed publications, accumulating 278 citations and an h-index of 9. His primary subject classification falls within Health Professions, with interdisciplinary engagement across public health, nutrition, health communication, and implementation research. The research portfolio demonstrates sustained attention to improving health outcomes through participatory and culturally informed intervention models.[1]

Research Contributions

  • Development of co-designed WASH communication strategies in Kiribati.
  • Systematic review of social and behaviour change communication interventions within nutrition-sensitive social protection programs.
  • Integration of co-design methodologies into formative research frameworks for low- and middle-income countries.
  • Research supporting obesity prevention communication strategies in Pacific Island contexts.

Publications

  • Co-designing water sanitation and hygiene (WASH) messages for a social and behaviour change campaign in Kiribati (2026).
  • Effect of Integrating Social and Behavior Change Communication Strategies in Nutrition-Sensitive Social-Protection Programs on Specific Nutritional Outcomes: A Systematic Review (2026).
  • Integrating co-design into formative research for a SBCC entry-point platform for nutrition-sensitive social protection programs (2025).
  • Conducting formative research during a pandemic threat to inform obesity prevention communication strategies in Tonga (2024).

Research Impact

The impact of Turk’s scholarship is reflected in its emphasis on practical implementation and community engagement. His studies support policymakers, public health practitioners, and development organizations seeking evidence-based approaches to behavioural change and nutrition improvement. The combination of systematic reviews, formative research, and co-design methods strengthens the applicability of findings across diverse health settings.[4]

Award Suitability

Tahir Turk’s contributions align with the objectives of the International Invention Awards by demonstrating innovation in health communication, participatory research design, and public health intervention development. The integration of behavioural science principles into real-world health programs illustrates scholarly originality and practical relevance. His research record provides evidence of sustained academic productivity and measurable scholarly influence within the field of health professions.[5]

Conclusion

The academic profile of Tahir Turk highlights a focused commitment to advancing public health through behavioural communication research, nutrition-sensitive programming, and participatory intervention design. His body of work contributes valuable insights for researchers and practitioners working to improve health outcomes through evidence-based and community-centered approaches.

References

  1. Elsevier. (n.d.). Scopus author details: Tahir Turk, Author ID 37091848000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=37091848000
  2. Public Health in Practice. (2026). Co-designing water sanitation and hygiene (WASH) messages for a social and behaviour change campaign in Kiribati.
    DOI: https://doi.org/10.1016/j.puhip.2026.100821
  3. Nutrition Reviews. (2026). Effect of Integrating Social and Behavior Change Communication Strategies in Nutrition-Sensitive Social-Protection Programs on Specific Nutritional Outcomes.
    DOI: https://doi.org/10.1093/nutrit/nuaf063
  4. PLOS One. (2025). Integrating co-design into formative research for a SBCC entry-point platform.
    DOI: https://doi.org/10.1371/journal.pone.0310288
  5. Health Promotion Journal of Australia. (2024). Conducting formative research during a pandemic threat to inform the development of an obesity prevention strategy in Tonga.
    DOI: https://doi.org/10.1002/hpja.821
  6. medRxiv Preprint. (2024). Integrating co-design into formative research for nutrition-sensitive social protection programs.
    DOI: https://doi.org/10.1101/2024.09.08.24313037

Leticia Szadai | Medicine and Dentistry | Best Researcher Award

Published on by Invention Awards

Best Researcher Award

Leticia Szadai
Lund University, Sweden

Leticia Szadai
Affiliation Lund University
Country Sweden
Google Scholar ID CNcrXOIAAAAJ
Documents 27
Citations 175
h-index 7
Subject Area Medicine and Dentistry
Event International Invention Awards

The Best Researcher Award recognizes researchers whose scholarly activities have contributed to the advancement of knowledge and innovation within their respective disciplines. Leticia Szadai of Lund University has developed a research profile centered on melanoma biology, proteomics, biomarker discovery, and translational cancer research. Her work integrates advanced molecular analysis with clinical applications, supporting improved understanding of melanoma progression, recurrence mechanisms, and therapeutic opportunities. Through collaborative research efforts, she has contributed to the generation of valuable datasets and analytical frameworks relevant to modern oncology research.[1]

Abstract

This article summarizes the academic achievements and research contributions of Leticia Szadai. Her work primarily focuses on melanoma proteomics, molecular pathology, biomarker identification, and translational oncology. Through participation in multidisciplinary investigations, she has contributed to the development of proteomic resources and analytical methods that support precision medicine approaches in cancer research.[2]

Keywords

Melanoma, Proteomics, Molecular Pathology, Biomarkers, Translational Medicine, Cancer Research, Precision Oncology, Tumor Biology.

Introduction

Advances in cancer research increasingly depend on interdisciplinary methodologies that connect molecular science with clinical practice. Leticia Szadai has contributed to this field through studies examining melanoma biology and the molecular factors associated with disease progression and recurrence. Her research reflects contemporary efforts to improve diagnostic and prognostic strategies through large-scale proteomic investigation.[3]

Research Profile

As a researcher affiliated with Lund University, Leticia Szadai has participated in projects involving molecular oncology, clinical proteomics, and translational medicine. Her publication record demonstrates engagement with collaborative international research initiatives focused on melanoma tissue analysis, mitochondrial regulation, immune response mechanisms, and biomarker discovery. These efforts contribute to the broader objective of enhancing evidence-based cancer management.[4]

Research Contributions

  • Contributed to studies establishing comprehensive melanoma proteome atlases.
  • Investigated molecular pathology and protein expression patterns in melanoma.
  • Explored mitochondrial dysfunction and immune response dysregulation associated with melanoma recurrence.
  • Participated in biomarker discovery using archived tumor samples and advanced proteomic technologies.
  • Supported research into kinase signaling pathways and translational applications in oncology.

Publications

  • The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome (2021).
  • The Human Melanoma Proteome Atlas—Defining the Molecular Pathology (2021).
  • Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence (2023).
  • Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out (2021).
  • A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma (2021).

Research Impact

The available citation metrics indicate that Leticia Szadai’s research outputs have attracted scholarly attention within oncology and translational medicine communities. Her involvement in high-impact collaborative studies has supported the development of proteomic resources that facilitate future investigations into melanoma progression, biomarker validation, and personalized therapeutic strategies. These contributions demonstrate measurable academic influence and continuing relevance to cancer research.[5]

Award Suitability

Leticia Szadai’s research portfolio aligns with the objectives of the International Invention Awards and the Best Researcher Award category. Her scholarly contributions reflect innovation in proteomic methodology, translational cancer research, and biomarker development. The combination of publication activity, collaborative leadership, and clinically relevant outcomes supports recognition for contributions to medicine and dentistry-related scientific advancement.[6]

Conclusion

Leticia Szadai has established a research profile characterized by rigorous investigation of melanoma biology and proteomics. Her contributions to translational oncology, biomarker discovery, and molecular pathology have supported scientific understanding of cancer mechanisms and potential clinical applications. These achievements provide a strong foundation for academic recognition through the Best Researcher Award.

References

  1. Elsevier. (n.d.). Google Scholar author details: Leticia Szadai
    https://scholar.google.com/citations?hl=hu&user=CNcrXOIAAAAJ
  2. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.451
  3. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Defining the Molecular Pathology. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.473
  4. Szadai L et al. (2023). Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.1495
  5. Szadai L et al. (2021). Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers.
    https://doi.org/10.3390/cancers13236105
  6. Velasquez E et al. (2021). A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.466

A. Marcell Szasz | Medicine and Dentistry | Excellence in Research Award

Published on by Invention Awards

Excellence in Research Award

A. Marcell Szasz
Semmelweis University, Hungary

A. Marcell Szasz
Affiliation Semmelweis University
Country Hungary
Scopus ID 24723204500
Documents 147
Citations 4,107
h-index 29
Subject Area Medicine and Dentistry
Event International Invention Awards
Google Scholar ID eeJzLNQAAAAJ

The Excellence in Research Award recognizes researchers whose scholarly activities demonstrate sustained contributions to scientific advancement, interdisciplinary collaboration, and measurable research impact. A. Marcell Szasz of Semmelweis University has developed a notable academic profile in medicine and cancer research through influential publications, biomarker studies, translational oncology investigations, and evidence-based clinical analyses.[1] His publication record and citation performance indicate significant engagement within the international scientific community.[2]

Abstract

A. Marcell Szasz has contributed to the fields of oncology, molecular medicine, prognostic biomarker analysis, and cancer outcome prediction. His research portfolio encompasses gene-expression studies, clinical meta-analyses, cancer progression modeling, and translational medical investigations. Through collaborations with international research teams, his work has informed understanding of disease mechanisms and patient stratification approaches in modern oncology.[2]

Keywords

Oncology, Biomarkers, Precision Medicine, Cancer Research, Meta-analysis, Gene Expression, Translational Medicine, Clinical Research.

Introduction

Research excellence is frequently evaluated through scientific influence, publication quality, citation impact, and contribution to knowledge development. Within this context, A. Marcell Szasz has established a scholarly presence through studies addressing cancer biology, prognostic biomarkers, and therapeutic outcomes. His work contributes to evidence-based approaches used in clinical and translational medicine.[3]

Research Profile

The researcher maintains a substantial publication portfolio consisting of 147 indexed documents, more than 4,100 citations, and an h-index of 29. His academic activity is primarily associated with medicine, oncology, pathology, molecular diagnostics, and clinical outcome assessment. These metrics reflect both productivity and sustained visibility within international scientific literature.[1]

Research Contributions

  • Investigation of microRNA regulation and metastatic progression in breast cancer.
  • Development and validation of transcriptomic biomarkers associated with survival outcomes.
  • Comprehensive meta-analyses supporting clinical decision-making in oncology.
  • Studies examining genomic alterations and evolutionary pathways of metastatic disease.

Publications

Among his most cited publications are studies on miR-31 and breast cancer metastasis, transcriptomic biomarker validation in gastric cancer, urachal carcinoma meta-analysis, tamoxifen-response biomarkers, and phylogenetic analyses of metastatic progression.[4] These works have received substantial scholarly attention and have been referenced extensively in subsequent research.

Research Impact

The citation performance associated with A. Marcell Szasz demonstrates broad engagement from researchers across oncology, pathology, molecular biology, and clinical medicine. His publications have contributed to methodological refinement, biomarker validation, and evidence synthesis efforts that support future investigations and clinical translation.[5]

Award Suitability

The Excellence in Research Award emphasizes scientific rigor, research influence, and sustained scholarly contribution. Based on publication metrics, citation impact, interdisciplinary collaborations, and documented contributions to cancer research, A. Marcell Szasz demonstrates characteristics commonly associated with distinguished academic achievement and research leadership.[6]

Conclusion

A. Marcell Szasz has contributed meaningfully to contemporary oncology research through studies addressing biomarkers, disease progression, and clinical outcomes. His publication record, citation profile, and participation in influential collaborative projects provide a strong foundation for recognition within an academic award framework focused on research excellence.

References

  1. Elsevier. (n.d.). Scopus author details: A. Marcell Szasz, Author ID 24723204500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24723204500
  2. Valastyan S., Reinhardt F., et al. (2009). miR-31 inhibits breast cancer metastasis. Cell.
    DOI: https://doi.org/10.1016/j.cell.2009.03.047
  3. Szász A.M., Lánczky A., et al. (2016). Cross-validation of survival associated biomarkers in gastric cancer. Oncotarget.
    DOI: https://doi.org/10.18632/oncotarget.10337
  4. Brown D., Smeets D., Székely B., Szasz A.M., et al. (2017). Phylogenetic analysis of metastatic progression in breast cancer. Nature Communications.
    DOI: https://doi.org/10.1038/ncomms14944
  5. Mihály Z., Kormos M., Lánczky A., et al. (2013). Gene expression-based biomarkers predicting outcome after tamoxifen treatment.
    DOI: https://doi.org/10.1007/s10549-013-2619-y
  6. Szarvas T., Módos O., Niedworok C., et al. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma.
    DOI: https://doi.org/10.1016/j.urolonc.2016.04.012

Hygon Mutavhatsindi | Infectious Diseases | Best Researcher Award

Published on by Invention Awards

Dr. Hygon Mutavhatsindi | Infectious Diseases | Best Researcher Award

Specialist Scientist, SAMRC, South Africa.

Hygon Mutavhatsindi is a Specialist Scientist at the South African Medical Research Council (SAMRC) with a robust background in biochemistry, molecular biology, and immunology. His research explores infectious diseases, particularly tuberculosis (TB), HIV, and COVID-19, using molecular and immunological techniques. Dr. Mutavhatsindi has made significant contributions to immunology and TB research, aiming to identify non-sputum biomarkers to improve TB diagnosis and treatment outcomes. His work has earned him national and international recognition, alongside numerous grants and awards.

Profile

Scopus

Orcid

Education 🎓

Dr. Hygon Mutavhatsindi began his academic journey at the University of Venda, where he earned a BSc in Biochemistry and Biology (2009-2012), followed by an Honours degree in Biochemistry in 2013. He continued to pursue advanced studies at the same institution, obtaining an MSc in Biochemistry (2014-2015). His passion for molecular biology led him to Stellenbosch University, where he completed his PhD in Molecular Biology (2016-2019). During his doctoral studies, Dr. Mutavhatsindi focused on cutting-edge research, contributing to scientific advancements in his field.

Following his PhD, Dr. Mutavhatsindi undertook a prestigious Postdoctoral Fellowship in Immunology at the University of Cape Town (2020-2023). During this period, he deepened his expertise in immunological research, working on projects that explored the intricate mechanisms of immune response. His postdoctoral work not only advanced his academic credentials but also positioned him at the forefront of immunological science, further strengthening his research profile and contributing to ongoing scientific discussions in molecular biology and immunology.

Experience 💼

Dr. Hygon Mutavhatsindi currently serves as a Specialist Scientist at the South African Medical Research Council (SAMRC), a role he began in February 2024. In this position, he leads research efforts in tuberculosis (TB) and immunology, supervises postgraduate students, and manages multiple research projects. Prior to this, he was a Scientific Officer at the Cape Town HVTN Immunology Laboratory (May 2023–January 2024), where he conducted clinical studies and flow cytometry experiments, contributing to crucial immunological research.

Before taking on these roles, Dr. Mutavhatsindi completed a Postdoctoral Research Fellowship at the University of Cape Town (February 2020–January 2023), where his work focused on TB and COVID-19 immunology. His academic journey began as a PhD Researcher at Stellenbosch University (June 2016–December 2019), where he specialized in identifying TB biomarkers and evaluating treatment responses, building a strong foundation for his later contributions to immunology and infectious disease research.

Research Interests 🔬

TB Biomarkers: Focuses on identifying reliable biomarkers for tuberculosis diagnosis and monitoring treatment efficacy.

Non-Sputum Diagnostic Methods: Investigates blood- and saliva-based biomarkers to develop non-sputum diagnostic alternatives for TB, making diagnosis easier in low-resource settings.

Immunological Responses: Studies the immune system’s response to infectious diseases, with an emphasis on TB, HIV, and COVID-19.

Infectious Disease Immunology: Explores the interactions between pathogens and host immune responses to enhance understanding of disease progression and treatment outcomes.

TB Treatment Monitoring: Aims to develop new methods for tracking patient progress during TB treatment through biomarker discovery.

Cross-Disease Immunology: Compares immune responses across different infectious diseases, seeking common biomarkers and pathways for broader diagnostic and therapeutic applications.

Awards 🏆

Awards and Grants:

UCT CIDRI-Africa Postdoctoral Fellowship (2020-2022)

Fogarty HIV-Associated TB Training Program (2020-2022)

NRF Postdoctoral Fellowship (2021-2022)

SAMRC Doctoral Internship Scholarship (2017-2019)

NRF PhD and Masters Scholarships

Publications Top Notes 📚 

Validation and optimisation of host immunological bio-signatures for a point-of-care test for TB disease – Front. Immunol., 2021. link

Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis – Tuberculosis, 2021. link

Protocol to quantify and phenotype SARS-CoV-2 specific T-cell response – Star Protocols, 2022. link

Blood and site of disease inflammatory profiles in HIV-1-infected pericardial tuberculosis patients – OFID, 2023. link

Application of cerebrospinal fluid host protein biosignatures in the diagnosis of tuberculous meningitis in children – Mediators of Inflammation, 2019. link